Keyword Search
 
2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011
DateTitle 
November 13, 2018OncoCyte Reports Third Quarter 2018 Financial Results and Progress in DetermaVu™ Development
Transition to New Diagnostic Testing Platform Complete Prospective R&D Validation Study Results Expected by Late 2018 or Early 2019 Development Plan Remains On-Track, Targeting Commercial Availability in 2H 2019 Conference Call Today at 4:30 pm ET ALAMEDA, Calif., Nov. 13, 2018 (GLOBE NEWSWIRE) --  OncoCyte Corporation (NYSE American: OCX), a developer of novel, non-invasive tests for the early detection of lung cancer, today reported financial and operating results for the third quarter... 
Printer Friendly Version
November 09, 2018Asterias Biotherapeutics Reports Third Quarter Results
Clinical Programs Continue to Progress Recent Transactions with affiliate of Novo Nordisk Increased Cash-on-Hand and Reduced Annual Operating Expenses Recently Announced Definitive Merger Agreement with BioTime Creates Leading Cell Therapy Company FREMONT, Calif., Nov. 09, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American: AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological conditions associated with demyelination and cell... 
Printer Friendly Version
November 06, 2018Oncocyte to Report Third Quarter 2018 Financial Results on November 13, 2018
ALAMEDA, Calif., Nov. 06, 2018 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American: OCX), a developer of novel, non-invasive tests for the early detection of cancer, announced today that it will release its financial and operating results for the third quarter ended September 30, 2018, on Tuesday, November 13, 2018, after the close of the U.S. financial markets. The Company will host a conference call on Tuesday, November 13, 2018, at 4:30 pm ET / 1:30 pm PT to discuss the results along wi... 
Printer Friendly Version
November 02, 2018Asterias Biotherapeutics to Report Third Quarter 2018 Results on November 12, 2018
FREMONT, Calif., Nov. 02, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American: AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological conditions associated with demyelination and cellular immunotherapies to treat cancer, today announced that it will release third quarter 2018 financial and operating results on Monday, November 12, 2018 after the close of the U.S. financial markets. The Company will host a conference call and webca... 
Printer Friendly Version
October 31, 2018Asterias Biotherapeutics Announces Positive Outcome from Data Review from OPC1 Spinal Cord Injury Study
Meeting with Food and Drug Administration Remains on Track for End of 2018 FREMONT, Calif., Oct. 31, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American: AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological conditions associated with demyelination and cellular immunotherapies to treat cancer, today announced a positive outcome from an independent Data Review Panel’s  review  of the data generated by patients enrolled in the C... 
Printer Friendly Version
October 29, 2018OncoCyte Completes Successful Transition to New Diagnostic Testing Platform and Initiates DetermaVu™ Development Studies
Initiates Algorithm Development Study to Establish Accuracy in Interpreting Assay Results On-Track for Pivotal R&D Validation Study Results by Approximately Year End, with Commercial Availability Planned for 2H 2019 ALAMEDA, Calif., Oct. 29, 2018 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American: OCX), a developer of novel, non-invasive tests for the early detection of cancer, today provided an update on its successful transition to a new diagnostic testing platform and initiation of... 
Printer Friendly Version
October 17, 2018OncoCyte Corporation to Present at the BIO CEO Investor Forum
ALAMEDA, Calif., Oct. 17, 2018 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American:OCX), a developer of novel, non-invasive tests for the early detection of cancer, today announced that William Annett, President and Chief Executive Officer, will provide a corporate overview at the BIO Investor Forum, being held October 17-18, 2018 in San Francisco, California. OncoCyte Corporation Presentation Details: Date:   Thursday, October 18 Time:  ... 
Printer Friendly Version
October 01, 2018Asterias Biotherapeutics Announces Facilities and IP License Option Agreements
Transactions Provide Additional Cash to Advance Clinical Programs and Process Development while Reducing Fixed Overhead FREMONT, Calif., Oct. 01, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American: AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological conditions associated with demyelination and cellular immunotherapies to treat cancer, today announced it has entered into two new agreements with an affiliate of Novo Nordisk, a ... 
Printer Friendly Version
September 20, 2018FDA Accepts Asterias Biotherapeutics’ Request to Meet and Discuss Next Phase of Development for OPC1 Spinal Cord Injury Clinical Program
FREMONT, Calif., Sept. 20, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American: AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological conditions associated with demyelination and cellular immunotherapies to treat cancer, today announced that the Food and Drug Administration (FDA) has accepted its request to meet to discuss proposed next steps for the OPC1 clinical development program. The Company’s Type B meeting request was made... 
Printer Friendly Version
September 12, 2018Asterias Provides 24 Month Cohort 2 Update for its OPC1 Phase 1/2a Clinical Trial in Severe Spinal Cord Injury
FREMONT, Calif., Sept. 12, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American: AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological conditions associated with demyelination and cellular immunotherapies to treat cancer, today provided additional data from the Company’s ongoing Phase 1/2a SCiStar study designed to evaluate the safety and potential efficacy of OPC1 in the treatment of severe cervical spinal cord injury. All 6 subj... 
Printer Friendly Version
September 04, 2018Asterias Biotherapeutics Announces Positive Outcome from Second Safety Review Committee Meeting and Open Enrollment for VAC2 Clinical Trial in Non-Small Cell Lung Cancer (NSCLC)
Two Sites in the UK Currently Enrolling Patients FREMONT, Calif., Sept. 04, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American: AST), a biotechnology company dedicated to developing cellular immunotherapies to treat cancer and cell-based therapeutics to treat neurological conditions associated with demyelination, today announced that the Safety Review Committee (SRC) for the first clinical trial of VAC2 has held its second scheduled meeting to review the safety and tolerab... 
Printer Friendly Version
August 29, 2018Asterias Biotherapeutics’ CEO Michael Mulroy to Participate on Regenerative Medicine Therapies Panel at the B. Riley FBR Healthcare Conference
FREMONT, Calif., Aug. 29, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American: AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological conditions associated with demyelination and cellular immunotherapies to treat cancer, today announced that Michael Mulroy, President and Chief Executive Officer, will participate in a panel discussion at the B. Riley FBR Healthcare Conference at 8:20am ET/5:20 am PT on Tuesday, September 4, 2018 in... 
Printer Friendly Version
August 16, 2018AgeX Therapeutics Acquires Technology to Regulate Immune Tolerance
Technology supports Company’s strategy for off-the-shelf (allogeneic) cell-based regenerative medicine products through the use of the HLA-G gene ALAMEDA, Calif.--(BUSINESS WIRE)--Aug. 16, 2018-- AgeX Therapeutics, Inc., a subsidiary of BioTime, Inc. (NYSE American: BTX), focused on the development and commercialization of novel therapeutics targeting human aging, today announced that it has acquired certain patents and patent applicati... 
Printer Friendly Version
August 14, 2018OncoCyte Reports Second Quarter 2018 Financial Results and Positive Corporate Developments
-Encouraging Study Data Drives Continued Development of DetermaVu™ Lung Cancer Diagnostic Test- -Conference Call Today at 4:30 pm ET- ALAMEDA, Calif., Aug. 14, 2018 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American: OCX), a developer of novel, non-invasive tests for the early detection of cancer, today reported financial and operating results for the second quarter ended June 30, 2018.  The Company ended the second quarter with $10.3 million in cash and cash equivalents and m... 
Printer Friendly Version
August 09, 2018Seasoned Healthcare Executive Albert P. Parker Appointed Chief Operating Officer of OncoCyte
ALAMEDA, Calif., Aug. 09, 2018 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American: OCX), a developer of novel, non-invasive liquid biopsy tests for the early detection of cancer, today announced the appointment of Albert P. Parker, a seasoned industry executive with over 25 years of pharmaceutical, biotech and healthcare experience, as Chief Operating Officer. “I welcome Al to OncoCyte and I, along with the other senior executives, look forward to his many contributions,” commented Wil... 
Printer Friendly Version
August 09, 2018Asterias Biotherapeutics Reports Second Quarter Financial Results and Recent Development Progress
Company Progressing Neurology and Immunotherapy Clinical Programs Anticipates Achievement of Significant Execution Milestones in the Second Half of 2018 and Full Year 2019 to Advance the Development of its Platform Technologies Conference Call and Webcast Today, August 9, at 5:00 p.m. ET FREMONT, Calif., Aug. 09, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American: AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological condit... 
Printer Friendly Version
July 31, 2018Asterias Provides 12 Month Cohort 3 and 4 Update for its AST-OPC1 Phase 1/2a Clinical Trial in Severe Spinal Cord Injury
-Company to Request Formal Meeting with FDA Under RMAT Designation this Quarter to Discuss Next Phase of Development for OPC Program- FREMONT, Calif., July 31, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American:AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological conditions associated with demyelination and cellular immunotherapies to treat cancer, today provided additional data from the Company’s ongoing Phase 1/2a SCiStar st... 
Printer Friendly Version
July 30, 2018OncoCyte to Report Second Quarter 2018 Financial Results on August 14, 2018
ALAMEDA, Calif., July 30, 2018 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American: OCX), a developer of novel, non-invasive liquid biopsy tests for the early detection of cancer, announced today that it will release its financial and operating results for the second quarter of 2018, ended June 30, 2018, on Tuesday, August 14, 2018, after the close of the U.S. financial markets. The Company will host a conference call on Tuesday, August 14, 2018, at 4:30 pm ET / 1:30 pm PT to discuss the r... 
Printer Friendly Version
July 27, 2018OncoCyte Announces At-Market $3.59 Million Offering of Common Stock and Warrants
ALAMEDA, Calif., July 27, 2018 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American:OCX), a developer of novel, non-invasive liquid biopsy diagnostic tests for the early detection of cancer, today announced that it has entered into definitive agreements with certain investors led by members of management and the Board of Directors as well as a new institutional investor for the purchase of units, with each consisting of one share of its common stock and one warrant to acquire one share of i... 
Printer Friendly Version
July 26, 2018Asterias Biotherapeutics to Report Second Quarter 2018 Results on August 9, 2018
FREMONT, Calif., July 26, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American:AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological conditions associated with demyelination and cellular immunotherapies to treat cancer, today announced that it will release second quarter 2018 financial and operating results on Thursday, August 9, 2018 after the close of the U.S. financial markets. The Company will host a conference call and webcas... 
Printer Friendly Version
July 17, 2018Asterias Provides Six Month Data Readout for its AST-OPC1 Phase 1/2a Clinical Trial in Severe Spinal Cord Injury
- Current Readout Includes New Six Month Data for Cohort 5 and Aggregate Trial Data - - Results Continue to Demonstrate Favorable Safety Profile, Potential for Durable Cell Engraftment at the Injury Site and Improved Motor Function - - 12 Month Top-Line Readout from the Entire SCiStar Study Expected in First Quarter of 2019 - FREMONT, Calif., July 17, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American:AST), a biotechnology company dedicated to developing cell-based thera... 
Printer Friendly Version
July 12, 2018Asterias Biotherapeutics Announces New Exclusive License Agreement with The Regents of the University of California for Stroke IP; Second Pre-Clinical Collaboration Initiated to Test the Efficacy of AST-OPC1 for the Treatment of Stroke
AST-OPC1 has Demonstrated Positive Safety Profile and Promising Signs of Efficacy in a Phase 1/2a Trial for Severe Spinal Cord Injury FREMONT, Calif., July 12, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American:AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological conditions associated with demyelination and cellular immunotherapies to treat cancer, today announced that it has entered into an exclusive license agreement with Th... 
Printer Friendly Version
July 11, 2018Asterias Biotherapeutics Announces Positive Outcome from Safety Review Committee for AST-VAC2; Recommends Continuation of Clinical Trial in Non-Small Cell Lung Cancer (NSCLC)
FREMONT, Calif., July 11, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American:AST), a biotechnology company dedicated to developing cellular immunotherapies to treat cancer and cell-based therapeutics to treat neurological conditions associated with demyelination, today announced that the Safety Review Committee (SRC) for the first clinical trial of AST-VAC2, held a scheduled meeting to review the safety and tolerability data generated in the first patient enrolled in the st... 
Printer Friendly Version
July 11, 2018AgeX Therapeutics CEO Dr. Michael D. West to Present at Ending Age-Related Diseases: Investment Prospects & Advances in Research, July 12 in New York City
ALAMEDA, Calif.--(BUSINESS WIRE)--Jul. 11, 2018-- AgeX Therapeutics, Inc., a subsidiary of BioTime, Inc. (NYSE American: BTX), today announced that Chief Executive Officer Michael D. West, Ph.D., who also serves as Co-CEO of BioTime, will present at the conference Ending Age-Related Diseases: Investment Prospects & Advances in Research, Thursday, July 12 at Cooper Union in New York City. Scheduled for 2:00pm EDT, Dr. West’s presenta... 
Printer Friendly Version
July 09, 2018OncoCyte Reports Encouraging New Study Results for Lung Cancer Blood Test
- Results suggest improved performance of next-generation test - Study results support move to new diagnostic testing platform - Significant development work required to fully validate this recent progress ALAMEDA, Calif., July 09, 2018 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American:OCX), a developer of novel tests for early detection of cancer, today reported that its most recent study of clinical samples in the development of DetermaVu™, its lung cancer diagnostic blood test, has... 
Printer Friendly Version
June 12, 2018Asterias Biotherapeutics Announces First Patient Dosed in First-in-Human Clinical Study of Immunotherapy AST-VAC2 in Non-Small Cell Lung Cancer
FREMONT, Calif., June 12, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE MKT:AST), a biotechnology company dedicated to developing cellular immunotherapies to treat cancer and cell-based therapeutics to treat neurological conditions associated with demyelination, today announced enrollment and dosing of the first subject in the first-in-human Phase 1 clinical trial of AST-VAC2 in the United Kingdom. This initial clinical trial, which is being sponsored, managed and funded by Can... 
Printer Friendly Version
June 11, 2018AgeX Therapeutics Closes on $5 Million Strategic Investment From Juvenescence
ALAMEDA, Calif.--(BUSINESS WIRE)--Jun. 11, 2018-- AgeX Therapeutics, Inc., a subsidiary of BioTime, Inc. (NYSE American: BTX), focused on prolonging healthspan through an understanding of the fundamental mechanisms of human aging, today announced that it has closed a $5 million equity financing, through the sale of two million AgeX common shares to Juvenescence Ltd. Following the sale, BioTime owns approximately 80.6% of AgeX’s outstanding ... 
Printer Friendly Version
June 05, 2018Asterias Biotherapeutics Announces Independent Data Monitoring Committee Completes Last Intermediate Review of AST-OPC1 Clinical Trial in Acute Spinal Cord Injury
- AST-OPC1 Safety Profile Continues To Be Favorable - FREMONT, Calif., June 05, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American:AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological conditions associated with demyelination and cellular immunotherapies to treat cancer, today announced that the independent Data Monitoring Committee (DMC) for the company’s SCiStar Phase 1/2a study of AST-OPC1 in acute spinal cord injury has c... 
Printer Friendly Version
June 05, 2018AgeX Therapeutics Appoints John F. Mauldin to Board of Directors
Bestselling financial writer and visionary joins AgeX Board as Company enters next phase of growth ALAMEDA, Calif.--(BUSINESS WIRE)--Jun. 5, 2018-- AgeX Therapeutics, Inc., a subsidiary of BioTime, Inc. (NYSE American: BTX) focused on prolonging healthspan through an understanding of the fundamental mechanisms of human aging, today announced the appointment of financial expert, commentator, and bestselling author John F. Mauldin to its ... 
Printer Friendly Version
May 17, 2018AgeX Therapeutics CEO Dr. Michael D. West to Deliver Keynote Address at World Advanced Therapies & Regenerative Medicine Congress, May 18 in London
ALAMEDA, Calif.--(BUSINESS WIRE)--May 17, 2018-- AgeX Therapeutics, Inc., a subsidiary of BioTime, Inc. (NYSE American: BTX), today announced that the company’s Chief Executive Officer Michael D. West, Ph.D., who also serves as Co-CEO of BioTime, will deliver a keynote presentation at World Advanced Therapies & Regenerative Medicine Congress, May 16-18 in London. Taking place on Friday, May 18 at 12:30pm BST, Dr. West’s presentation... 
Printer Friendly Version
May 16, 2018Asterias Biotherapeutics to Discuss Cancer Immunotherapy Product AST-VAC2 at the World Advanced Therapies and Regenerative Medicine Congress
FREMONT, Calif., May 16, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE MKT:AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological conditions associated with demyelination and cellular immunotherapies to treat cancer, today announced that Rob Allen, Asterias’ Senior Director of Immunotherapy, will discuss the Company’s cancer immunotherapy product candidate, which is poised to enter the clinic this quarter with the anticipated start o... 
Printer Friendly Version
May 15, 2018OncoCyte Reports First Quarter 2018 Financial Results
Conference Call Today at 4:30 pm ET ALAMEDA, Calif., May 15, 2018 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American:OCX), a developer of novel, non-invasive tests for the early detection of cancer, today reported financial and operating results for the first quarter ended March 31, 2018. “We have completed initial sample testing and begun analyzing the data collected in the confirmation study of our DetermaVu™ lung cancer diagnostic test. This study is being conducted on alternative di... 
Printer Friendly Version
May 09, 2018Asterias Biotherapeutics Reports First Quarter Financial Results and Recent Development Progress
-  AST-VAC2 Immunotherapy Program Prepares to Enter Clinic in Second Quarter of 2018 – - Conference Call and Webcast Today, May 9, at 5:00 p.m. ET – FREMONT, Calif., May 09, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE MKT:AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological conditions associated with demyelination and cellular immunotherapies to treat cancer, today reported financial and operational results for the quarter ende... 
Printer Friendly Version
May 08, 2018OncoCyte to Report First Quarter 2018 Financial Results on May 15, 2018
ALAMEDA, Calif, May 08, 2018 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American:OCX), a developer of novel, non-invasive liquid biopsy tests for the early detection of cancer, announced today that it will release its financial and operating results for the first quarter of 2018, ended March 31, 2018, on Tuesday, May 15, 2018, after the close of the U.S. financial markets. The Company will host a conference call on Tuesday, May 15, 2018, at 4:30 pm ET / 1:30 pm PT to discuss the results al... 
Printer Friendly Version
May 03, 2018Asterias Biotherapeutics to Report First Quarter 2018 Results on May 9, 2018
FREMONT, Calif., May 03, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American:AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological conditions associated with demyelination and cellular immunotherapies to treat cancer, today announced that it will release first quarter 2018 financial and operating results on Wednesday, May 9, 2018 after the close of the U.S. financial markets. The Company will host a conference call and webcast on... 
Printer Friendly Version
May 02, 2018Asterias Biotherapeutics to Present Safety and Efficacy Data from AST-OPC1 SCiStar Study at the American Spinal Injury Association (ASIA) 2018 Annual Meeting                                                                         
FREMONT, Calif., May 02, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE MKT:AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological conditions associated with demyelination and cellular immunotherapies to treat cancer, today announced that Edward Wirth III, M.D., Ph.D., Asterias’ Chief Medical Officer, will present previously announced 12-month safety and efficacy results for Cohort 2 (subjects with AIS-A grade cervical spinal cord inj... 
Printer Friendly Version
May 02, 2018AgeX Announces NIH Grant Award
Grant of Approximately $386,000 Will Enable Company to Accelerate its Clinical Development Programs for the Treatment of Diseases of Aging ALAMEDA, Calif.--(BUSINESS WIRE)--May 2, 2018-- AgeX Therapeutics, Inc., a subsidiary of BioTime, Inc. (NYSE American: BTX), today announced the award of a grant of approximately $386,000 from the National Institute of Neurological Disorders and Stroke of the National Institutes of Health (NIH). The ... 
Printer Friendly Version
April 27, 2018Asterias Biotherapeutics to Present AST-OPC1 Program Update at the Upcoming American Society for Neural Therapy and Repair Conference
FREMONT, Calif., April 27, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE MKT:AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological conditions associated with demyelination and cellular immunotherapies to treat cancer, today announced that Nate Manley, Asterias’ Associate Director of Neurobiology, will present an AST-OPC1 program update at the American Society for Neural Therapy and Repair INTR-15 Conference, which is being held duri... 
Printer Friendly Version
April 25, 2018Asterias Announces Clinical Grade Lot Released to Support Dosing of First Subjects in First Clinical Study of AST-VAC2
-Release of clinical grade lot of AST-VAC2 is key step in Cancer Research UK’s initiation of clinical study in Non-Small Cell Lung Cancer - FREMONT, Calif., April 25, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American:AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological conditions associated with demyelination and cellular immunotherapies to treat cancer, today announced that Cancer Research UK has released the first cGMP (cur... 
Printer Friendly Version
April 03, 2018Leading Molecular Diagnostics Executive Ronnie Andrews Appointed to OncoCyte’s Board of Directors
ALAMEDA, Calif., April 03, 2018 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American:OCX) today announced the appointment of Ronald Andrews, Jr., an executive with over 30 years’ experience in the molecular diagnostics and genomics industries, to the Company’s Board of Directors. The appointment of Mr. Andrews brings the number of directors to seven and the number of independent directors to four. “Ronnie comes to us with an extensive background in the molecular diagnostics industry, str... 
Printer Friendly Version
April 02, 2018OncoCyte Reports Fourth Quarter and Full Year 2017 Financial Results
Development of DetermaVu™ Remains on Track for Completion in 2018 -Conference Call Today at 4:30 pm ET- ALAMEDA, Calif., April 02, 2018 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American:OCX), a developer of novel, non-invasive liquid biopsy tests for the early detection of cancer, today reported financial results for the fourth quarter and full year ended December 31, 2017. “Since our last quarterly update to investors in November, the team at OncoCyte has been busy making substanti... 
Printer Friendly Version
April 02, 2018OncoCyte Files Patents for 190 Newly Identified Novel Lung Cancer Biomarkers
New biomarkers could assist in differentiating malignant from benign lung nodules for improved lung cancer diagnosis ALAMEDA, Calif., April 02, 2018 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American:OCX), a developer of novel, non-invasive liquid biopsy diagnostic tests for the early detection of cancer, strengthened its intellectual property portfolio as it filed global patent applications for 190 newly identified novel biomarkers. These new biomarkers may enhance OncoCyte’s lung cance... 
Printer Friendly Version
April 02, 2018OncoCyte Names Cavan Redmond Chairman of the Board of Directors
ALAMEDA, Calif., April 02, 2018 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American:OCX) today announced that Cavan Redmond, a director of the Company since 2015, has been named Chairman of the Board of Directors. Alfred D. Kingsley, who has been Chairman since 2009 and was instrumental in forming OncoCyte and in taking it public in 2015, will remain a director.  Mr. Redmond’s career brings a unique combination of R&D and commercial experience in biotechnology and consumer healthcare. H... 
Printer Friendly Version
March 29, 2018OncoCyte to Report Fourth Quarter and Full Year 2017 Financial Results on April 2, 2018
ALAMEDA, Calif., March 29, 2018 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American:OCX), a developer of novel, non-invasive liquid biopsy tests for the early detection of cancer, announced today that it will release its financial and operating results for the fourth quarter and full year 2017, ended December 31, 2017, on Monday, April 2, 2018, after the close of the U.S. financial markets. The Company will host a conference call on Monday, April 2, 2018, at 4:30 p.m. ET / 1:30 p.m. PT to ... 
Printer Friendly Version
March 28, 2018OncoCyte Announces the Closing of a $10 Million Private Placement of Common Stock
ALAMEDA, Calif., March 28, 2018 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American:OCX), a developer of novel, non-invasive liquid biopsy diagnostic tests for the early detection of cancer, today announced that it has closed a private placement of its common stock with two of its current investors. The purchase agreement for the private placement committed the investors to purchase 7,936,508 shares of common stock for $1.26 per share, for total gross proceeds of $10.0 million before deduc... 
Printer Friendly Version
March 15, 2018Asterias Biotherapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Recent Developments
- Achieved Meaningful Progress with Key Clinical Programs - - Anticipate Multiple Data Readouts from SCiStar Study in 2018 into First Quarter of 2019 - - Expect to Enroll First Subject in AST-VAC2 Randomized Clinical Trial in NSCLC in Second Quarter - - Conference Call and Webcast Today, March 15, at 5:00 p.m. ET - FREMONT, Calif., March 15, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American:AST), a biotechnology company dedicated to developing cell-based therapeutics t... 
Printer Friendly Version
March 09, 2018Asterias Biotherapeutics to Report Fourth Quarter and Full Year 2017 Results on March 15, 2018
FREMONT, Calif., March 09, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American:ST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological conditions associated with demyelination and cellular immunotherapies to treat cancer, today announced that it will release fourth quarter and full year 2017 financial and operating results on Thursday, March 15, 2018 after the close of the U.S. financial markets. The Company will host a conference c... 
Printer Friendly Version
March 08, 2018OncoCyte Announces Initial Results of DetermaVu™ Feasibility on New Platforms; Enhancements May Increase Lung Cancer Diagnostic Test’s Clinical Performance
Company Anticipates Commercial Launch During 2018 ALAMEDA, Calif., March 08, 2018 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American:OCX), a developer of novel, non-invasive liquid biopsy tests for the early detection of cancer, today provided an update on the development and commercial launch timeline of DetermaVu™, its liquid biopsy lung cancer diagnostic test. As reported in November 2017, during the process of running initial samples for the Clinical Validation Study inconsistent ... 
Printer Friendly Version
March 01, 2018AgeX Therapeutics CEO Dr. Michael D. West to Present at Three Conferences in March 2018
ALAMEDA, Calif.--(BUSINESS WIRE)--Mar. 1, 2018-- AgeX Therapeutics, Inc., a subsidiary of BioTime, Inc. (NYSE American: BTX) today announced that the company’s Chief Executive Officer Michael D. West, Ph.D. will participate at three upcoming conferences: the Mauldin Economics Strategic Investment Conference, March 6-9 in San Diego; Undoing Aging, March 15-17 in Berlin, Germany; and the 10th World Congress and Expo on Cell & Stem Cell Resear... 
Printer Friendly Version
February 15, 2018Asterias Expands Global IP Portfolio with New Patents, Including Key Additional Patent Protection for its Cancer Immunotherapy Program
FREMONT, Calif., Feb. 15, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American:AST), a biotechnology company dedicated to developing regenerative medicine therapeutics to treat neurological conditions associated with de-myelination and cellular immunotherapies to treat cancer, today announced that it has strengthened its global IP portfolio over the past 12 months with the issuance of 46 new patents, including in the United States, Europe, Japan, Canada, China, Australia, Isr... 
Printer Friendly Version
January 18, 2018AgeX CEO Michael D. West to Present in Plenary Session at The World Stem Cell Summit on “Stem Cell Innovations That Will Change the World”
ALAMEDA, Calif.--(BUSINESS WIRE)--Jan. 18, 2018-- AgeX Therapeutics, Inc., a subsidiary of BioTime, Inc. (NYSE American: BTX), today announced that AgeX will present in a Plenary session, “Stem Cell Innovations That Will Change the World – Part 2,” at the World Stem Cell Summit (WSCS) on Thursday, January 25, 2018 at the Hyatt Regency Miami. AgeX CEO Michael D. West, Ph.D. will provide an update on AgeX’s core programs in cardiovascular and... 
Printer Friendly Version
January 05, 2018AgeX Therapeutics to Present at Biotech Showcase Annual Conference
ALAMEDA, Calif.--(BUSINESS WIRE)--Jan. 5, 2018-- AgeX Therapeutics, Inc., a subsidiary of BioTime, Inc. (NYSE American: BTX), today announced that it will present at Biotech Showcase, January 8-10, 2018 at the Hilton San Francisco Union Square. Michael D. West, Ph.D., Chief Executive Officer, will present at the conference as follows: Date: Tuesday, January 9 Time: 2:30 PM PST Track: Yosemite-B (Ballroom Level) Venue: Hil... 
Printer Friendly Version
January 04, 2018Asterias Biotherapeutics Reports Milestone Targets for 2018
FREMONT, Calif., Jan. 04, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American:AST), a biotechnology company pioneering the field of regenerative medicine, today provided its 2018 milestones targets for its spinal cord injury and cancer immunotherapy programs after successfully achieving its milestones for 2017.  These achievements, combined with the Company’s financial resources position Asterias to achieve the following milestones during 2018. ANTICIPATED 2018 MILESTONES... 
Printer Friendly Version
January 02, 2018AgeX Therapeutics Identifies Genes Implicated in Tissue Regeneration and Cancer
- Published in the peer-reviewed journal Oncotarget – - Potential applications in scarless tissue regeneration, cancer, and aging - ALAMEDA, Calif.--(BUSINESS WIRE)--Jan. 2, 2018-- AgeX Therapeutics, Inc. (AgeX), a subsidiary of BioTime, Inc. (NYSE American: BTX), today announced a newly-published peer-reviewed study that reveals genes implicated in tissue regeneration, cancer, and aging. The study, by scientists at AgeX and ... 
Printer Friendly Version